APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antibody-siRNA Drug Conjugates

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antibody-siRNA Drug Conjugates Market Outlook and Growth Opportunities 2026

5 June 2026190 pages

Choose your research edition.

Industry ResearchAntibody-siRNA Drug Conjugates Industry Research Report 2026104 pages · $2,950 USDIndustry Growth & TrendsGlobal Antibody-siRNA Drug Conjugates Industry Growth and Trends Forecast to 203262 pages · $3,450 USDMarket StructureGlobal Antibody-siRNA Drug Conjugates Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antibody-siRNA Drug Conjugates Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Antibody-siRNA Drug Conjugates Market Analysis and Forecast 2026-2032184 pages · $4,950 USD

Market perspective

The global Antibody-siRNA Drug Conjugates market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antibody-siRNA Drug Conjugates is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antibody-siRNA Drug Conjugates is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antibody-siRNA Drug Conjugates is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antibody-siRNA Drug Conjugates market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antibody-siRNA Drug Conjugates market include Avidity Biosciences and Dyne Therapeutics among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Antibody-siRNA Drug Conjugates market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antibody-siRNA Drug Conjugates and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antibody-siRNA Drug Conjugates revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Antibody-siRNA Drug Conjugates market.

Antibody-siRNA Drug Conjugates Segment by Company

Avidity Biosciences

Dyne Therapeutics

Antibody-siRNA Drug Conjugates Segment by Type

Full-Length Antibodies Based

Antigen-Binding Fragments Based

Antibody-siRNA Drug Conjugates Segment by Application

Facioscapulohumeral Muscular Dystrophy

Duchenne Muscular Dystrophy

Muscular Dystrophy Type 1

Other

Antibody-siRNA Drug Conjugates Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Antibody-siRNA Drug Conjugates status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Antibody-siRNA Drug Conjugates key companies, revenue, market share, and recent developments.

3. To split the Antibody-siRNA Drug Conjugates breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Antibody-siRNA Drug Conjugates market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antibody-siRNA Drug Conjugates significant trends, drivers, influence factors in global and regions.

6. To analyze Antibody-siRNA Drug Conjugates competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody-siRNA Drug Conjugates market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antibody-siRNA Drug Conjugates and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody-siRNA Drug Conjugates.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antibody-siRNA Drug Conjugates industry.

Chapter 3: Detailed analysis of Antibody-siRNA Drug Conjugates company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Antibody-siRNA Drug Conjugates in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Antibody-siRNA Drug Conjugates in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antibody-siRNA Drug Conjugates Industry Trends Table 2. Antibody-siRNA Drug Conjugates Industry Drivers Table 3. Antibody-siRNA Drug Conjugates Industry Opportunities and Challenges Table 4. Antibody-siRNA Drug Conjugates Industry Restraints Table 5. Global Antibody-siRNA Drug Conjugates Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antibody-siRNA Drug Conjugates Revenue Share by Company (2021-2026) Table 7. Global Antibody-siRNA Drug Conjugates Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Antibody-siRNA Drug Conjugates Key Company Manufacturing Base & Headquarters Table 9. Global Antibody-siRNA Drug Conjugates Company, Product Type & Application Table 10. Global Antibody-siRNA Drug Conjugates Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Antibody-siRNA Drug Conjugates by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Full-Length Antibodies Based Table 15. Significant Companies of Antigen-Binding Fragments Based Table 16. Global Antibody-siRNA Drug Conjugates Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Antibody-siRNA Drug Conjugates Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Antibody-siRNA Drug Conjugates Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Antibody-siRNA Drug Conjugates Sales Value Share by Type (2021-2026) Table 20. Global Antibody-siRNA Drug Conjugates Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Facioscapulohumeral Muscular Dystrophy Table 22. Significant Companies of Duchenne Muscular Dystrophy Table 23. Significant Companies of Muscular Dystrophy Type 1 Table 24. Significant Companies of Other Table 25. Global Antibody-siRNA Drug Conjugates Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Antibody-siRNA Drug Conjugates Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Antibody-siRNA Drug Conjugates Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Antibody-siRNA Drug Conjugates Sales Value Share by Application (2021-2026) Table 29. Global Antibody-siRNA Drug Conjugates Sales Value Share by Application (2027-2032) Table 30. Global Antibody-siRNA Drug Conjugates Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Antibody-siRNA Drug Conjugates Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Antibody-siRNA Drug Conjugates Sales Value Share by Region (2021-2026) Table 33. Global Antibody-siRNA Drug Conjugates Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Antibody-siRNA Drug Conjugates Sales Value Share by Region (2027-2032) Table 35. Global Antibody-siRNA Drug Conjugates Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Antibody-siRNA Drug Conjugates Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Antibody-siRNA Drug Conjugates Sales Value Market Share by Country (2021-2026) Table 38. Global Antibody-siRNA Drug Conjugates Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Antibody-siRNA Drug Conjugates Sales Value Market Share by Country (2027-2032) Table 40. Avidity Biosciences Company Information Table 41. Avidity Biosciences Business Overview Table 42. Avidity Biosciences Antibody-siRNA Drug Conjugates Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Avidity Biosciences Antibody-siRNA Drug Conjugates Product Portfolio Table 44. Avidity Biosciences Recent Development Table 45. Dyne Therapeutics Company Information Table 46. Dyne Therapeutics Business Overview Table 47. Dyne Therapeutics Antibody-siRNA Drug Conjugates Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Dyne Therapeutics Antibody-siRNA Drug Conjugates Product Portfolio Table 49. Dyne Therapeutics Recent Development Table 50. Research Programs/Design for This Report Table 51. Authors List of This Report Table 52. Secondary Sources Table 53. Primary Sources List of Figures Figure 1. Antibody-siRNA Drug Conjugates Product Image Figure 2. Global Antibody-siRNA Drug Conjugates Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antibody-siRNA Drug Conjugates Market Size (2021-2032) & (US$ Million) Figure 4. Global Antibody-siRNA Drug Conjugates Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Full-Length Antibodies Based Image Figure 8. Antigen-Binding Fragments Based Image Figure 9. Global Antibody-siRNA Drug Conjugates Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Antibody-siRNA Drug Conjugates Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Antibody-siRNA Drug Conjugates Sales Value Share by Type (2021-2032) Figure 12. Facioscapulohumeral Muscular Dystrophy Image Figure 13. Duchenne Muscular Dystrophy Image Figure 14. Muscular Dystrophy Type 1 Image Figure 15. Other Image Figure 16. Global Antibody-siRNA Drug Conjugates Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Antibody-siRNA Drug Conjugates Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Antibody-siRNA Drug Conjugates Sales Value Share by Application (2021-2032) Figure 19. Global Antibody-siRNA Drug Conjugates Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Antibody-siRNA Drug Conjugates Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Antibody-siRNA Drug Conjugates Sales Value (2021-2032) & (US$ Million) Figure 22. North America Antibody-siRNA Drug Conjugates Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Antibody-siRNA Drug Conjugates Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Antibody-siRNA Drug Conjugates Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Antibody-siRNA Drug Conjugates Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Antibody-siRNA Drug Conjugates Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Antibody-siRNA Drug Conjugates Sales Value (2021-2032) & (US$ Million) Figure 28. South America Antibody-siRNA Drug Conjugates Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Antibody-siRNA Drug Conjugates Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Antibody-siRNA Drug Conjugates Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Full-Length Antibodies Based
  • Antigen-Binding Fragments Based
Applications
  • Facioscapulohumeral Muscular Dystrophy
  • Duchenne Muscular Dystrophy
  • Muscular Dystrophy Type 1
  • Other
Companies covered
  • Avidity Biosciences
  • Dyne Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antibody-siRNA Drug Conjugates Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antibody-siRNA Drug Conjugates Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Antibody-siRNA Drug Conjugates Market Dynamics
  1. 2.1 Antibody-siRNA Drug Conjugates Industry Trends
  2. 2.2 Antibody-siRNA Drug Conjugates Industry Drivers
  3. 2.3 Antibody-siRNA Drug Conjugates Industry Opportunities and Challenges
  4. 2.4 Antibody-siRNA Drug Conjugates Industry Restraints
3 Antibody-siRNA Drug Conjugates Market by Company
  1. 3.1 Global Antibody-siRNA Drug Conjugates Company Revenue Ranking in 2025
  2. 3.2 Global Antibody-siRNA Drug Conjugates Revenue by Company (2021-2026)
  3. 3.3 Global Antibody-siRNA Drug Conjugates Company Ranking (2024-2026)
  4. 3.4 Global Antibody-siRNA Drug Conjugates Company Manufacturing Base and Headquarters
  5. 3.5 Global Antibody-siRNA Drug Conjugates Company Product Type and Application
  6. 3.6 Global Antibody-siRNA Drug Conjugates Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Antibody-siRNA Drug Conjugates Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Antibody-siRNA Drug Conjugates Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Antibody-siRNA Drug Conjugates Market by Type
  1. 4.1 Antibody-siRNA Drug Conjugates Type Introduction
  2. 4.1.1 Full-Length Antibodies Based
  3. 4.1.2 Antigen-Binding Fragments Based
  4. 4.2 Global Antibody-siRNA Drug Conjugates Sales Value by Type
  5. 4.2.1 Global Antibody-siRNA Drug Conjugates Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Antibody-siRNA Drug Conjugates Sales Value by Type (2021-2032)
  7. 4.2.3 Global Antibody-siRNA Drug Conjugates Sales Value Share by Type (2021-2032)
5 Antibody-siRNA Drug Conjugates Market by Application
  1. 5.1 Antibody-siRNA Drug Conjugates Application Introduction
  2. 5.1.1 Facioscapulohumeral Muscular Dystrophy
  3. 5.1.2 Duchenne Muscular Dystrophy
  4. 5.1.3 Muscular Dystrophy Type 1
  5. 5.1.4 Other
  6. 5.2 Global Antibody-siRNA Drug Conjugates Sales Value by Application
  7. 5.2.1 Global Antibody-siRNA Drug Conjugates Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Antibody-siRNA Drug Conjugates Sales Value by Application (2021-2032)
  9. 5.2.3 Global Antibody-siRNA Drug Conjugates Sales Value Share by Application (2021-2032)
6 Antibody-siRNA Drug Conjugates Regional Value Analysis
  1. 6.1 Global Antibody-siRNA Drug Conjugates Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antibody-siRNA Drug Conjugates Sales Value by Region (2021-2032)
  3. 6.2.1 Global Antibody-siRNA Drug Conjugates Sales Value by Region: 2021-2026
  4. 6.2.2 Global Antibody-siRNA Drug Conjugates Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antibody-siRNA Drug Conjugates Sales Value (2021-2032)
  7. 6.3.2 North America Antibody-siRNA Drug Conjugates Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Antibody-siRNA Drug Conjugates Sales Value (2021-2032)
  10. 6.4.2 Europe Antibody-siRNA Drug Conjugates Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Antibody-siRNA Drug Conjugates Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Antibody-siRNA Drug Conjugates Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Antibody-siRNA Drug Conjugates Sales Value (2021-2032)
  16. 6.6.2 South America Antibody-siRNA Drug Conjugates Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Antibody-siRNA Drug Conjugates Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Antibody-siRNA Drug Conjugates Sales Value Share by Country, 2025 VS 2032
7 Antibody-siRNA Drug Conjugates Country-level Value Analysis
  1. 7.1 Global Antibody-siRNA Drug Conjugates Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antibody-siRNA Drug Conjugates Sales Value by Country (2021-2032)
  3. 7.2.1 Global Antibody-siRNA Drug Conjugates Sales Value by Country (2021-2026)
  4. 7.2.2 Global Antibody-siRNA Drug Conjugates Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Antibody-siRNA Drug Conjugates Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Antibody-siRNA Drug Conjugates Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Antibody-siRNA Drug Conjugates Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Avidity Biosciences
  2. 8.1.1 Avidity Biosciences Company Information
  3. 8.1.2 Avidity Biosciences Business Overview
  4. 8.1.3 Avidity Biosciences Antibody-siRNA Drug Conjugates Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Avidity Biosciences Antibody-siRNA Drug Conjugates Product Portfolio
  6. 8.1.5 Avidity Biosciences Recent Developments
  7. 8.2 Dyne Therapeutics
  8. 8.2.1 Dyne Therapeutics Company Information
  9. 8.2.2 Dyne Therapeutics Business Overview
  10. 8.2.3 Dyne Therapeutics Antibody-siRNA Drug Conjugates Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Dyne Therapeutics Antibody-siRNA Drug Conjugates Product Portfolio
  12. 8.2.5 Dyne Therapeutics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst